According to EU recommendations, timely and accurate in-vitro COVID-19 testing in the laboratories in any healthcare facility is an essential part of the management of COVID-19 for slowing down the pandemic.
Test kits use blood drawn from a finger prick by a phlebotomist. In-vitro diagnostics can detect the virus at different stages of incubation, which can be used to monitor a person’s overall health to help cure, treat and even prevent the deadly disease COVID-19.
Right now, the rapid COVID-19 tests are being used worldwide by patients, as well as their physicians, in order to make accurate, reliable and clinically meaningful medical decisions.
The rapid antibody tests for COVID-19, could alleviate the pressure on laboratories and expand testing capacity to meet the most urgent medical and public health needs. In addition, the test has proved its efficiency in detecting asymptomatic cases that could further spread the virus, if not isolated.
For COVID-19, SIFSOF rapid tests take around 10-15 minutes to generate the results compared to about four hours or more for molecular tests, if samples must be transported to a distant testing laboratory.
SIFSOF in-vitro rapid COVID-19 tests, such as the SIFTESTCVD-1.0, are relatively simple to perform and interpret and therefore require limited test operator training. They may be intended either for use in hospital laboratories or near the point-of-care.